Skip to content

Venture

Screen Shot 2019-08-01 at 2.24.13 PM

Affiliations

University of Connecticut

Technologies

Therapeutic

Indication

Autoimmune & Inflammation

Drug Discovery

Oncology

Personalized Medicine

Additional Information

Women Founded

DeMay Bio is developing a biologic drug for Rheumatoid Arthritis that leverages a natural human protein to target a novel, but validated, disease mechanism directly in the joints. The new drug is an adjunct therapy, to be used alongside a patient’s immunosuppressant regimen,  to achieve better disease control, and to reduce disabling joint pain, tissue damage and mobility loss.

 

DeMay Bio Team:

Caroline Dealy